Literature DB >> 22450988

Efficacy of ceftobiprole Medocaril against Enterococcus faecalis in a murine urinary tract infection model.

Kavindra V Singh1, Barbara E Murray.   

Abstract

We evaluated ceftobiprole against the well-characterized Enterococcus faecalis strain OG1RF (with and without the β-lactamase [Bla] plasmid pBEM10) in a murine urinary tract infection (UTI) model. Ceftobiprole was equally effective for Bla(+) and Bla(-) OG1 strains, while ampicillin was moderately to markedly (depending on the inoculum) less effective against Bla(+) than Bla(-) OG1 strains. These data illustrate an in vivo effect on ampicillin of Bla production by E. faecalis and the stability and efficacy of ceftobiprole in experimental UTI.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22450988      PMCID： PMC3370727          DOI： 10.1128/AAC.06102-11

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  33 in total

1.  BAL9141, a novel extended-spectrum cephalosporin active against methicillin-resistant Staphylococcus aureus in treatment of experimental endocarditis.

Authors:  J M Entenza; P Hohl; I Heinze-Krauss; M P Glauser; P Moreillon
Journal:  Antimicrob Agents Chemother       Date:  2002-01       Impact factor: 5.191

2.  In vivo synergism of ceftobiprole and vancomycin against experimental endocarditis due to vancomycin-intermediate Staphylococcus aureus.

Authors:  J M Entenza; T R Veloso; J Vouillamoz; M Giddey; P Majcherczyk; P Moreillon
Journal:  Antimicrob Agents Chemother       Date:  2011-07-05       Impact factor: 5.191

3.  Generation of restriction map of Enterococcus faecalis OG1 and investigation of growth requirements and regions encoding biosynthetic function.

Authors:  B E Murray; K V Singh; R P Ross; J D Heath; G M Dunny; G M Weinstock
Journal:  J Bacteriol       Date:  1993-08       Impact factor: 3.490

4.  Treatment of experimental endocarditis caused by a beta-lactamase-producing strain of Enterococcus faecalis with high-level resistance to gentamicin.

Authors:  R G Hindes; S H Willey; G M Eliopoulos; L B Rice; C T Eliopoulos; B E Murray; R C Moellering
Journal:  Antimicrob Agents Chemother       Date:  1989-07       Impact factor: 5.191

5.  Development of a long-term ascending urinary tract infection mouse model for antibiotic treatment studies.

Authors:  H Hvidberg; C Struve; K A Krogfelt; N Christensen; S N Rasmussen; N Frimodt-Møller
Journal:  Antimicrob Agents Chemother       Date:  2000-01       Impact factor: 5.191

6.  Nucleotide sequence of the beta-lactamase gene from Enterococcus faecalis HH22 and its similarity to staphylococcal beta-lactamase genes.

Authors:  K K Zscheck; B E Murray
Journal:  Antimicrob Agents Chemother       Date:  1991-09       Impact factor: 5.191

7.  Transferable beta-lactamase. A new mechanism for in vitro penicillin resistance in Streptococcus faecalis.

Authors:  B E Murray; B Mederski-Samaroj
Journal:  J Clin Invest       Date:  1983-09       Impact factor: 14.808

8.  Bactericidal activity and synergy studies of BAL9141, a novel pyrrolidinone-3-ylidenemethyl cephem, tested against streptococci, enterococci and methicillin-resistant staphylococci.

Authors:  L M Deshpande; R N Jones
Journal:  Clin Microbiol Infect       Date:  2003-11       Impact factor: 8.067

9.  Multiple-dose pharmacokinetics and safety of a novel broad-spectrum cephalosporin (BAL5788) in healthy volunteers.

Authors:  Anne Schmitt-Hoffmann; Lars Nyman; Brigitte Roos; Michael Schleimer; Jill Sauer; Norman Nashed; Thomas Brown; Anthony Man; Erhard Weidekamm
Journal:  Antimicrob Agents Chemother       Date:  2004-07       Impact factor: 5.191

10.  Efficacy of BAL5788, a prodrug of cephalosporin BAL9141, in a mouse model of acute pneumococcal pneumonia.

Authors:  E Azoulay-Dupuis; J P Bédos; J Mohler; A Schmitt-Hoffmann; M Schleimer; S Shapiro
Journal:  Antimicrob Agents Chemother       Date:  2004-04       Impact factor: 5.191
View more
  5 in total

1.  Efficacy of Omadacycline against Escherichia coli in a Mouse Urinary Tract Infection Model.

Authors:  Kavindra V Singh; Barbara E Murray
Journal:  Antimicrob Agents Chemother       Date:  2021-06-17       Impact factor: 5.191

2.  Histopathological changes induced in an animal model by potentially pathogenic Enterococcus faecalis strains recovered from ready-to-eat food outlets in Osun State, Nigeria.

Authors:  Adetunji Kola Olawale; Oluwole Moses David; Adekemi Olubukunola Oluyege; Richard Temitope Osuntoyinbo; Solomon Anjuwon Laleye; Oladiran Famurewa
Journal:  Infect Drug Resist       Date:  2015-06-26       Impact factor: 4.003

3.  Bioactivity Studies of β-Lactam Derived Polycyclic Fused Pyrroli-Dine/Pyrrolizidine Derivatives in Dentistry: In Vitro, In Vivo and In Silico Studies.

Authors:  Gowri Meiyazhagan; Rajesh Raju; Sofi Beaula Winfred; Bhavani Mannivanan; Hemadev Bhoopalan; Venkatesh Shankar; Sathiya Sekar; Deepa Parvathi Venkatachalam; Ravishankar Pitani; Venkateshbabu Nagendrababu; Malini Thaiman; Kandaswamy Devivanayagam; Jeyakanthan Jayaraman; Raghunathan Ragavachary; Ganesh Venkatraman
Journal:  PLoS One       Date:  2015-07-17       Impact factor: 3.240

Review 4.  New antibiotics for bad bugs: where are we?

Authors:  Matteo Bassetti; Maria Merelli; Chiara Temperoni; Augusta Astilean
Journal:  Ann Clin Microbiol Antimicrob       Date:  2013-08-28       Impact factor: 3.944

5.  The effect of antibiotics on the gut microbiome: a metagenomics analysis of microbial shift and gut antibiotic resistance in antibiotic treated mice.

Authors:  Lei Xu; Anil Surathu; Isaac Raplee; Ashok Chockalingam; Sharron Stewart; Lacey Walker; Leonard Sacks; Vikram Patel; Zhihua Li; Rodney Rouse
Journal:  BMC Genomics       Date:  2020-03-30       Impact factor: 3.969
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.